BACKGROUND The Neuroform Atlas stent™ (by Stryker, Fremont, California) represents the most recent widely available upgrade to intracranial stenting, providing a laser cut open cell stent with a diameter of 3.0 to 4.5 mm that is delivered through an 0.017-inch microcatheter. OBJECTIVE To report our initial multicenter experience of the safety, efficacy, and feasibility of the Atlas stent used for treating aneurysms, as well as one case of intracranial stenosis and one carotid artery dissection as well as other pathologies. METHODS A retrospective multicenter study of subjects treated with Atlas stent during the period 2018 to 2019. RESULTS The total number of patients included in our analysis was 71 patients. The stent was utilized to treat 69 aneurysm cases. Of the aneurysms, 36% presented with acute rupture and 56% of the ruptured aneurysms were high grade. Mean aneurysm dimension was 7 mm with an average neck width of 4.1 mm. Around 30% had received prior treatment. Telescoping or Y-stent was used in 16% of cases. We did not observe any symptomatic major complications in our series. Asymptomatic major complications were seen in 7 patients (10.1%); technical complications occurred in 4.3%. Immediate modified Raymond-Roy-occlusion-outcome class I/II was observed in 87%, and this increased to 97.7% at latest follow-up, which was at 4 mo; 91.8% of patients achieved favorable clinical outcome, and mortality rate was 1.4%. CONCLUSION Our series demonstrates the safety, feasibility, and efficacy of the Atlas stent. The low complication rate and the high obliteration rate managing complex aneurysms, even in an acute ruptured setting, are notable.

中文翻译：

---

Neuroform Atlas 支架的早期多中心体验：可行性、安全性和有效性

背景 Neuroform Atlas 支架 TM （由 Stryker，Fremont，California 提供）代表了颅内支架的最新广泛可用升级，提供了直径为 3.0 至 4.5 毫米的激光切割开孔支架，通过 0.017 英寸微导管输送。目的 报告我们关于 Atlas 支架用于治疗动脉瘤的安全性、有效性和可行性的初步多中心经验，以及 1 例颅内狭窄和 1 例颈动脉夹层以及其他病理。方法 对 2018 年至 2019 年期间接受 Atlas 支架治疗的受试者进行的一项回顾性多中心研究。 结果 我们分析的患者总数为 71 名。该支架用于治疗69例动脉瘤病例。在动脉瘤中，36% 表现为急性破裂，56% 的破裂动脉瘤为高级别。平均动脉瘤尺寸为 7 毫米，平均颈部宽度为 4.1 毫米。大约 30% 的人曾接受过预先治疗。16% 的病例使用了伸缩式或 Y 型支架。我们在我们的系列中没有观察到任何有症状的主要并发症。7 名患者（10.1%）出现无症状的主要并发症；技术并发症发生率为 4.3%。87% 的患者观察到立即改良 Raymond-Roy 咬合结果 I/II 级，并且在最近一次随访时增加到 97.7%，即 4 个月；91.8%的患者取得了良好的临床结果，死亡率为1.4%。结论 我们的系列证明了 Atlas 支架的安全性、可行性和有效性。管理复杂动脉瘤的低并发症发生率和高闭塞率，